The global acute repetitive seizures market size is projected to hit around US$ 18.5 billion by 2030 and register a compound annual growth rate (CAGR) of about 46.7% from 2022 to 2030.
The global acute repetitive seizures market size is projected to hit around US$ 18.5 billion by 2030 and register a compound annual growth rate (CAGR) of about 46.7% from 2022 to 2030.
Patients with drug-resistant epilepsy often experience acute repeated seizures. The terms cluster seizure, breakthrough seizure, seizure flurry, serial seizure, seizure cluster, and extended seizure are also used to describe it. Acute repetitive seizure is characterized by frequent seizures that might happen within hours or even minutes of one another. The frequency of these seizures varies on the patient’s features and the type of epilepsy they have, such as mesial temporal lobe epilepsy. Women with mesial temporal lobe epilepsy experience three catamenial seizures within two days before their period. Acute repeated seizures are treated with rectal gels and nasal sprays.
Get the sample copy of the report@ https://www.precedenceresearch.com/sample/1164
Market Growth
Emerging administration methods for treating epileptic seizures, novel pharmacological therapies, and hereditary variables associated with brain abnormalities and epileptic seizures are a few of the key reasons propelling the growth of the global market for treating epileptic seizures. Additionally, the prevalence of head injuries, cardiovascular illness, brain tumors, drug addiction, and infections are increasing, which is driving up the demand for epileptic seizure therapy globally.
Increased numbers of patients with status epileptics and acute repeated seizures are the key factors driving the growth of the market for treatments for epileptic seizures. High unmet clinical needs for patients and caregivers, as well as the availability of cutting-edge product pipelines, are two key factors projected to drive market expansion.
Product Insight
Acute repetitive seizures are categorized into Diastat Rectal Gel, NRL-1, USL-261, AZ-002, and others on the basis of product. Due to its skill and the lack of FDA-approved medications on the market in 2021, Diastat Rectal Gel held the lion’s share of the revenue stake. It is the only FDA-approved medication, and generic versions were made public in 2010. Patients prefer the intra-nasal route above the rectal, buccal, and intramuscular routes among the several ways to administer medications. Parenteral drugs have proven to be the best option for outpatient care. However, in a select few countries, such as the Netherlands, caregivers lack the skills necessary to manage parenteral drugs.
What is the Regional Analysis in the Acute Repetitive Seizures Market?
In 2021, the market for the treatment of epileptic seizures and acute repetitive seizures was dominated by North America. The rise in neurological illnesses, recent medicine approvals, rise in brain traumas, and a well-established healthcare system all lend credence to this trend. During the estimated period, North America is anticipated to maintain its pattern.
Furthermore, the market for pharmaceuticals for acute repeated seizures is anticipated to grow quickly in Europe as a result of an increase in government funding, an increase in R&D spending in the field of neurology, and a rise in the demand for these drugs.
Due to a larger population of people with epilepsy, increased awareness of epileptic seizures, increased emphasis on improving healthcare infrastructure, an increase in the number of elderly people, and a growing number of market players reaffirming their presence in the region, Asia Pacific is predicted to grow at a faster rate during the estimated period.
Ask Here for Customization@ https://www.precedenceresearch.com/customization/1164
Report Scope
| Report Coverage | Details |
| Market Size By 2030 | US$ 18.5 Billion |
| Growth Rate From 2022 to 2030 | CAGR of 46.7% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered |
|
| Regions Covered |
|
Here are some prominent players in the Acute Repetitive Seizures Market
- Neurelis, Inc.
- UCB S.A.
- Valeant Pharmaceuticals North America LLC
- Alexza Pharmaceuticals
- Others
Market Dynamics of Acute Repetitive Seizures Market
Market Drivers
One of the key drivers anticipated to drive market expansion is the high number of unmet clinical needs for patients and caregivers, as well as the availability of an advanced product pipeline. The majority of people with cluster seizures respond well to drug therapy. Governments all over the world are constantly working to lower the expenses of hospital stays and on-site patient treatment through outpatient care models, such as clinic and home healthcare, in an effort to reduce overall healthcare spending. These healthcare reforms are being adopted more frequently in developing nations like China and India. The market for acute repeated seizures is anticipated to expand as a result of this factor.
Market Restraints
The foundation of the technological sector, small and medium-sized businesses have seen a sharp decline in sales since the epidemic began in 2020. Thus, as supply chain interruptions were noted, market participants faced a number of difficulties.
Market Opportunities
Acute Repetitive Seizures Market growth is primarily attributed to the increase in seizure diseases, greater public awareness of acute repetitive seizures and available treatments, and technical developments in seizure monitoring and diagnosis. Fast-track regulatory approvals for novel antiepileptic medications and a focus on the treatment of acute repeated seizures by major market players are further reasons.
Recent Development of Acute Repetitive Seizures Market
- In September 2018, the Pharmaceutical business Neurelis, Inc. submitted a New Drug NDA to the FDA for VALTOCO, a therapy for epilepsy patients experiencing acute repeated seizures.
- January 2020, According to Neurelis, the U.S. FDA has approved the diazepam nasal spray VALTOCO® as an acute treatment for people with epilepsy 6 years of age and older who experience intermittent, stereotypical episodes of repeated seizure movement that are different from a patient’s usual seizure pattern. For dependable and consistent absorption, Intravail® is part of the unique formulation of VALTOCO.
- In May 2019, the latest anti-epileptic medicine (AED) from UCB, NAYZILAM® nasal spray CIV, was approved for a New Drug Application by the U.S. FDA. It is a benzodiazepine used for people with epilepsy 12 years of age and older who experience stereotypical occurrences of recurring seizure activity and acute treatment of intermittent that differ from the patient’s typical seizure form1. The first and only FDA-approved nasal option for the management of seizure clusters is NAYZILAM, which is provided to patients and carers.
Market Segmentation
Product Outlook
- NRL-1
- Diastat Rectal Gel
- USL-261
- AZ-002
- Others
By Application
- Hospitals
- Clinics
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Click Here to View Full Report Table of Contents
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/1164
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333